Clinical Trials Sponsored by Mesoblast, Inc.

Total 35583 results

Mesoblast, Inc.

Completed

Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)

Graft Vs Host Disease

United States
Mesoblast, Inc.

Completed

Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Crohn's Disease

United States, Canada, New Zealand, Australia
Mesoblast, Inc.

Completed

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Crohn's Disease

United States, New Zealand, Australia
Mesoblast, Inc.

No longer available

Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute Graft Versus Host Disease (GVHD)

Graft-Versus-Host Disease

United States
Mesoblast, Inc.

Completed

Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD)

Graft Versus Host Disease

United States, Australia, Canada
Mesoblast, Inc.

Completed

Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)

Myocardial Infarction

United States, Canada
Mesoblast, Inc.

Completed

Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure. (DREAM HF-1)

Chronic Heart Failure

United States, Canada
Mesoblast, Inc.

Completed

Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease

Crohn's Disease

United States, Canada
Mesoblast, Inc.

Completed

PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive | Pulmonary Emphysema | Chronic Bronchitis

United States
Mesoblast, Inc.

No longer available

Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHD

Graft vs Host Disease | Graft-Versus-Host Disease

United States, Canada
Mesoblast, Inc.

Completed

Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction (AMICI)

Acute Myocardial Infarction
Mesoblast, Inc.

Completed

Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)

Graft Versus Host Disease

United States, Italy, Australia, Canada, Switzerland, United Kingdom
Mesoblast, Inc.

Completed

Safety and Efficacy of Prochymal® for the Salvage of Treatment-Refractory Acute GVHD Patients

Graft Versus Host Disease

United States
Mesoblast, Inc.

Completed

Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease

Crohn's Disease

United States
Mesoblast, Inc.

Completed

Safety Study of Adult Mesenchymal Stem Cells (MSC) to Treat Acute Myocardial Infarction

Myocardial Infarction

United States
Mesoblast, Inc.

No longer available

Safety and Treatment Outcome Study of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects With Treatment-resistant Crohn's Disease

Crohn's Disease

United States
Mesoblast, Inc.
Quintiles, Inc.

Completed

A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)

Grade B aGVHD | Grade C aGVHD | Grade D aGVHD

United States
Mesoblast, Inc.
Quintiles, Inc.

Completed

Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD

Grade B Acute Graft Versus Host Disease | Grade C Acute Graft Versus Host Disease | Grade D Acute Graft Versus Host Disease

United States
Mesoblast International Sàrl

No longer available

Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection

Moderate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19

United States
Mesoblast, Inc.
Juvenile Diabetes Research Foundation

Completed

PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)

Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent | Juvenile Diabetes

United States
Mesoblast, Ltd.
Quintiles, Inc.

Completed

Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain (MSB-DR003)

Degenerative Disc Disease

United States, Australia
Mesoblast, Ltd.

Not yet recruiting

Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain (HyaluronicAcid)

Degenerative Disc Disease
Mesoblast, Ltd.

Completed

Safety and Preliminary Efficacy Study of NeoFuse in Subjects Requiring Lumbar Interbody Fusion

Degenerative Disc Disease | Spinal Stenosis | Degenerative Spondylolisthesis

United States
Mesoblast International Sàrl

Available

Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)

Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)
Mesoblast International Sàrl

Completed

Follow-up Study of Chondrogen® Delivered by Intra-Articular Injection Following Meniscectomy

Recovery Following Partial Medial Meniscectomy

United States
The Cleveland Clinic
Mesoblast, Inc.

Recruiting

Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis

Crohn Colitis

United States
The Cleveland Clinic
Mesoblast, Inc.

Recruiting

Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC) (UC)

Ulcerative Colitis

United States
Mesoblast, Ltd.

Completed

Study of 3 Doses of NeoFuse Combined With MasterGraft Granules in Subjects Requiring Posterolateral Lumbar Fusion (PLF)

Degenerative Disc Disease | Spinal Stenosis | Spondylolisthesis

United States
Mesoblast, Ltd.

Completed

P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies

Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Hodgkin's Disease

United States
Mesoblast, Ltd.

Completed

Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes

Type 2 Diabetes

United States
Mesoblast, Ltd.

Completed

Safety and Preliminary Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy

Spinal Stenosis | Cervical Degenerative Disc Disease | Degenerative Spondylolisthesis

United States
Mesoblast, Ltd.

Completed

Safety and Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy and Fusion

Spinal Stenosis | Cervical Degenerative Disc Disease | Degenerative Spondylolisthesis

Australia
Mesoblast, Ltd.

Completed

Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain

Degenerative Disc Disease

United States, Australia
Mesoblast, Ltd.

Withdrawn

Safety and Efficacy Study of NeoFuse in Subjects Requiring Posterolateral Lumbar Fusion

Degenerative Disc Disease | Spinal Stenosis | Degenerative Spondylolisthesis

United States
Mesoblast, Ltd.

Completed

A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure

Heart Failure

United States
Mesoblast, Ltd.

Completed

Safety and Efficacy Study of MSB-CAR001 in Subjects 6 Weeks Post an Anterior Cruciate Ligament Reconstruction

Osteoarthritis | Anterior Cruciate Ligament Injury

Australia
Mesoblast, Ltd.

Completed

Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy

Diabetic Nephropathy | Type 2 Diabetes

Australia
Mesoblast, Ltd.
PPD

Completed

A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor

Rheumatoid Arthritis

United States, Australia
Mesoblast International Sàrl
National Cancer Institute (NCI)

Withdrawn

OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies

Myelodysplastic Syndromes | Leukemia | Graft Versus Host Disease

United States
Icahn School of Medicine at Mount Sinai
National Heart, Lung, and Blood Institute (NHLBI); Mesoblast, Inc.

Terminated

MSCs in COVID-19 ARDS

COVID | Acute Respiratory Distress Syndrome | Mesenchymal Stromal Cells | Remestemcel-L

United States
IND Diagnostic Inc.

Unknown

Evaluation of the IND One Step Strep A Rapid Test vs. Culture

Strep Throat

United States
Mesoblast International Sàrl
University of Southern California; OrthoIndy; TRIA Orthopaedic Center; Midwest... and other collaborators

Completed

A Phase I/II Study of Chondrogen Delivered by Intra-Articular Injection Following Meniscectomy

Recovery Following Partial Medial Meniscectomy

United States
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.; Oncoceutics, Inc.

Recruiting

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Metastasis | Endometrial Cancer

United States
NC Medial Research Inc

Recruiting

A Study of NCS-01 in Patients With Acute Ischemic Stroke

Ischemic Stroke

United States
IC-IT Sciences Inc.

Unknown

Comparison of the Natural Frequencies Technology Sleep Patches to Sham Patches During Sleep in the Home Environment

Sleep Disturbance

United States
Zhengzhou Gensciences Inc
Haimen Gensciences lnc

Completed

An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.

Hemophilia A

China
Zhengzhou Gensciences Inc
Jiangsu Gensciences lnc.

Completed

Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A (RH-107-III02)

Hemophilia A

China
UNC Lineberger Comprehensive Cancer Center
Veracyte, Inc.

Recruiting

Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA (HARMONY)

Breast Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Seagen Inc.

Active, not recruiting

BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma

Lymphoma | Lymphatic Diseases | Adult T-Cell Leukemia/Lymphoma

United States
IGC Pharma LLC

Completed

Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease

Dementia of Alzheimer Type

Puerto Rico

3

Subscribe